ASO vs QURE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ASO and QURE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ASO and QURE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Academy Sports and Outdoors is one of the largest sporting goods and outdoor recreation retailers in the United States, operating large-format stores concentrated across Texas and the broader South and Southeast. Its assortment spans apparel, footwear, team and individual sports equipment, hunting, fishing, camping and other outdoor gear, plus patio, grills and outdoor-living goods, all merchandised around a value, everyday-low-price positioning that aims to undercut specialty rivals. A meaningful share of sales comes from a portfolio of private-label brands such as Magellan Outdoors, BCG, Game Winner and Freely, which the company reports made up roughly a fifth of merchandise sales in fiscal 2025 and which typically carry better margins than national brands.

Full ASO guide

uniQure N.V. is a Netherlands-based, Nasdaq-listed clinical-stage biotech developing adeno-associated virus (AAV) gene therapies for serious central-nervous-system and other genetic diseases. Its lead program is AMT-130, a one-time gene therapy for Huntington's disease, delivered surgically into the brain, that met its primary endpoint at three years with roughly 75% slowing of disease progression versus external controls in a Phase I/II study. The rest of the pipeline is earlier stage: AMT-162 for SOD1 ALS, AMT-260 for refractory mesial temporal lobe epilepsy, and AMT-191 for Fabry disease. The company already validated its platform once by developing Hemgenix, the hemophilia B gene therapy now commercialized by CSL Behring, which produces royalty income.

Full QURE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ASO drivers: New-store expansion beyond the South; Private-label brands and margin mix.
• QURE drivers: AMT-130 accelerated-approval path; First-mover position in Huntington's.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is discretionary-spending cyclicality: Academy sells goods consumers can delay buying, so a weaker labor market, inflation in essentials, or lower confidence can pressure comparable sales and margins quickly. For QURE, uniQure is a single-asset biotech, so any negative surprise on AMT-130, whether a Complete Response Letter, a request for a controlled confirmatory trial before approval, manufacturing questions, or safety concerns from an invasive brain-delivery procedure, could sharply reduce the company's value.

Pick ASO if you believe its drivers more; QURE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ASO and QURE guides.

ASO. These points are qualitative and directional as of the asOf date; they are not precise financials. Retail earnings can swing on a single season's weather, promotional intensity, or consumer conditions, so a low multiple may reflect cyclical risk rather than a clear bargain. Always verify current revenue, earnings, margins, dividend, share count, and analyst views from the latest filings and a live quote before acting.

QURE. uniQure is pre-profit, so traditional valuation multiples like P/E do not apply and the stock is valued on the probability-weighted potential of its pipeline, chiefly AMT-130. Product revenue is minimal, with most of the small top line coming from Hemgenix royalties and license deals, while the company runs large losses funding development. The large cash balance relative to the market cap is a distinguishing feature, giving runway through the planned Q3 2026 BLA submission and beyond.

Headline figures (approximate, Jul 2026): ASO shows business model Value big-box sporting goods and outdoor retailer; revenue driven by store count, comparable sales, and private-label mix, recent trend Q1 fiscal 2026 total sales rose in the mid-single digits with positive comparable sales; ecommerce and the outdoor category were relative outperformers (verify latest filing), growth plan Guided to roughly 20 to 25 new store openings in 2026 and has spoken to a longer-run goal of surpassing $8 billion in revenue, margins Gross margin supported by private-label penetration (about a fifth of fiscal 2025 merchandise sales); discretionary retail margins are sensitive to promotions and freight; QURE shows revenue (q1 2026) ~$3.6M (mostly license and royalty), net loss (q1 2026) ~$53.5M (~$0.85 per share), r&d expense (q1 2026) ~$29M, cash and investments ~$587M (into 2H 2029 runway).

ASO and QURE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ASO and QURE exposure against your real portfolio. It is not an investment adviser.